TABLE 3.

Drug susceptibility test results of phase II^a

Drug and concn (μg/ml)	No. of strains for which the indicated concn is the MIC						Total no. (%) of tests
	Site 1		Site 2		Site 3
	MGIT	460	MGIT	460	MGIT	460	MGIT	460
Amikacin
≤0.5	11	12	14	15	11	10	36 (57.1)	37 (58.7)
1.0	4	3	1	1	4	6	9 (14.3)	10 (15.9)
2.0	1	1	1	0	1	0	3 (4.8)	1 (1.6)
>2.0	5	5	5	5	5	5	15 (23.8)	15 (23.8)
Capreomycin
≤0.625	0	10	10	13	1	7	11 (17.5)	30 (47.6)
1.25	14	4	4	2	13	7	31 (49.2)	13 (20.6)
2.5	0	2	0	2	0	2	0 (0)	6 (9.5)
>2.5	7	5	7	4	7	5	21 (33.3)	14 (22.2)
Ethionamide
≤1.25	3	5	3	5	3	6	9 (14.3)	16 (25.4)
2.5	1	0	0	2	1	0	2 (3.2)	2 (3.2)
5.0	1	6	1	9	3	6	5 (7.9)	21 (33.3)
>5.0	16	10	17	5	14	9	47 (74.6)	24 (38.1)
Protionamide
≤0.625	4	6	2	7	3	7	9 (14.3)	20 (31.8)
1.25	0	4	2	4	4	3	6 (9.5)	11 (17.5)
2.5	4	2	4	5	5	5	13 (20.6)	12 (19.1)
>2.5	13	9	13	5	9	6	35 (55.6)	20 (31.8)
Ofloxacin
≤0.5	8	9	11	15	8	6	27 (42.9)	30 (47.6)
1.0	9	8	6	2	9	11	24 (38.1)	21 (33.3)
2.0	0	1	0	1	0	0	0 (0)	2 (3.2)
>2.0	4	3	4	3	4	4	12 (19.1)	10 (15.9)
Rifabutin
≤0.25	4	4	2	4	2	4	8 (12.7)	12 (19.1)
0.5	0	0	2	0	2	0	4 (6.3)	0 (0)
1.0	0	0	0	4	0	0	0 (0)	4 (6.3)
>1.0	17	17	17	13	17	17	51 (81.0)	47 (74.6)
Linezolid
≤0.5	19	19	15	21	21	21	55 (87.3)	61 (96.8)
1.0	2	2	4	0	0	0	6 (9.5)	2 (3.2)
2.0	0	0	2	0	0	0	2 (3.2)	0 (0)
>2.0	0	0	0	0	0	0	0 (0)	0 (0)

^aA total of 21 strains were tested. MGIT, BACTEC MGIT 960. 460, BACTEC 460.